340B at 30 and the Impending Cliff on the Road to 40


As the 340B program passes the 30-year mark, seminal events in the program’s history have shaped the landscape we see today. Far from being a bureaucratic regulation that all parties sleepily adopt, the 340B program has become a hot button for all those involved as well as those seeking to impact it from beyond the typical Covered Entity, Manufacturer, and Government participants. With so many dollars at stake, attention –and tension– is riding high on actions by the existing stakeholders that have made a significant impact on the program in ways that were unimaginable a few short years ago. 

Watch Tim Paine, Principal Consultant at Blue Fin Group, an IntegriChain Company as he discusses these changes and their impact on patients, payers, and manufacturers and estimates where the 340B program will be in the next 10 years.



Tim Paine
Principal Consultant
Blue Fin Group, An IntegriChain Company



adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article